You are here : Home > News Archive > CARBOGEN AMCIS AG Partners with ...
CARBOGEN AMCIS AG Partners with NextPharma Technologies

Agreement combines production and drug product services for highly potent APIs

6 October 2009

BUBENDORF, Switzerland (Oct. 06, 2009) ó Switzerland-based CARBOGEN AMCIS AG, a pharmaceutical process development and active pharmaceutical ingredient (API) manufacturing company, recently partnered with NextPharma to provide customers with seamless development services covering highly potent (HiPo) APIs and drug products. NextPharma is a leading European provider of product development, contract manufacturing, and cold chain and logistics outsourcing services to the pharmaceutical and biotech industries.

The alliance offers a complete range of services to customers for both the API and drug product, to provide material for pre-clinical and clinical trials. The joint services will result in reduced cycle times and risks, related to the delivery of customersí development projects.

"This alliance offers considerable added value to CARBOGEN AMCIS customers," said Charlie Johnson, CARBOGEN AMCIS, High Potency business manager. "Itís difficult to find reliable API production and drug product service companies in the HiPo arena; this agreement eliminates that challenge for customers."

CARBOGEN AMCIS will focus on API support with categorization, assessment, development, validation, manufacturing, scale-up and regulatory assistance. NextPharma will provide drug product development services for pre-formulation, formulation design and optimization, validation, manufacturing, scale-up, stability studies, clinical trial services, release and regulatory support.

"Our customers continuously look for ways to speed up development and reduce costs; this alliance moves customers one step closer to achieving these goals," said Sean Marett, managing director, NextPharma Technologies, Product Development Services.


CARBOGEN AMCIS AG is a leading service provider, offering a portfolio of drug-development and commercialization services to the pharmaceutical and biopharmaceutical industry at all stages of drug development. The integrated services provide innovative chemistry solutions to support timely and safe drug development allowing customers to make the best use of available resources. CARBOGEN AMCIS AG is owned by Dishman Pharmaceuticals and chemicals Ltd., Ahmedabad, India.

NextPharma Technologies, headquartered in the UK and founded in 2000, is a world class outsourcing partner to the pharmaceutical and biotechnology industry. The company offers a full range of services, from early phase product development to clinical trial packaging to high volume commercial manufacturing. NextPharma is a world leader in lyophilization, sterile fill finish and pellet technologies. The company also specializes in product manufacturing, including cytotoxics, hormones, penicillins, cephalosporins and narcotics.

11 August 2016
Dishman Celebrates a Decade of Success Since Acquisition of CARBOGEN AMCIS

14 July 2016
CARBOGEN AMCIS Sites at Aarau and Neuland in Switzerland Successfully Pass FDA Inspection

31 May 2016
CARBOGEN AMCIS Expands Operations in Bubendorf

World ADC Berlin

DCAT week - New York City